Journal
CELL HOST & MICROBE
Volume 25, Issue 1, Pages 49-+Publisher
CELL PRESS
DOI: 10.1016/j.chom.2018.12.005
Keywords
-
Categories
Funding
- Department of Defense [HDTRA1-13-C-0018]
- Department of Health and Human Services' NIH [U19AI109711, U19AI109762, AI132256]
- Public Health Agency of Canada (PHAC)
- Office of the Assistant Secretary for Preparedness and Response
- Biomedical Advanced Research and Development Authority (BARDA) [HHSO100201700023C]
- Irma T. Hirschl/Monique Weill-Caulier Research Award
Ask authors/readers for more resources
Recent and ongoing outbreaks of Ebola virus disease (EVD) underscore the unpredictable nature of ebolavirus reemergence and the urgent need for antiviral treatments. Unfortunately, available experimental vaccines and immunotherapeutics are specific for a single member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against other ebolaviruses associated with EVD, including Sudan virus (SUDV) and Bundibugyo virus (BDBV). Here we show that MBP134(AF), a pan-ebolavirus therapeutic comprising two broadly neutralizing human antibodies (bNAbs), affords unprecedented effectiveness and potency as a therapeutic countermeasure to antigenically diverse ebolaviruses. MBP134(AF) could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg dose was sufficient to protect NHPs against all three viruses. The development of MBP134(AF) provides a successful model for the rapid discovery and translational advancement of immunotherapeutics targeting emerging infectious diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
